Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.

Proteomics - 1 Dec 2006

David Della C, Ittner Lars M, Gehrig Peter, Nergenau Denise, Shepherd Claire, Halliday Glenda, Götz Jürgen

Abstract excerpt

Alzheimer's disease (AD) is characterized by Abeta peptide-containing plaques and tau-containing neurofibrillary tangles (NFTs). Both pathologies have been combined by crossing Abeta plaque-forming APP mutant mice with NFT-forming P301L tau mutant mice or by stereotaxically injecting beta-amyloid peptide 1-42 (Abeta42) into brains of P301L tau mutant mice. In cell culture, Abeta42 induces filamentous tau...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Nerve Tissue Proteins

Share to Protein Folding

Share to Proteomics

Share to Recombinant Proteins

Share to tau Proteins

Source

Identifiers

PMID: 17111439
DOI: 10.1002/pmic.200600634

Genes

APP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.PMID 17111439Read ↗

Oligomeric amyloid-β induces early and widespread changes to the proteome in human iPSC-derived neurons.Semantic proximity Read ↗

Comparative analysis of brain-derived tau oligomer interactomes in Alzheimer's disease, non-demented with Alzheimer's neuropathology, and primary age-related tauopathy: Implications for neurodegeneration and cognitive resilienceSemantic proximity Read ↗

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s DiseaseSemantic proximity Read ↗

Phosphorylated tau interactome in the human Alzheimer’s disease brainSemantic proximity Read ↗

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40.Semantic proximity Read ↗

Physiological Tau Interactome in Brain and Its Link to TauopathiesSemantic proximity Read ↗

Proteomic analysis of plasma from a Tau transgenic mouse.Semantic proximity Read ↗

Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.Semantic proximity Read ↗

Proteomics analysis of the neurodegeneration in the brain of tau transgenic mice.Semantic proximity Read ↗

Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivoSemantic proximity Read ↗

The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative DiseasesSemantic proximity Read ↗

β-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.